Consider Holding Febuxostat in Patients Admitted with CV Disease

Please see the February 2019 FDA advisory concerning the increased risk of death with Uloric (Febuxostat).

You'll hear about an advocacy group pushing for withdrawal of the gout med febuxostat (Uloric)...due to concerns it increases mortality.

We know patients with gout are already at elevated CV risk.

And early studies signaled a higher risk of CV events in patients on febuxostat compared to allopurinol...so FDA required a safety trial.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals